Idenix Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Enyo Pharma

Southern Research Institute

Msd International Gmbh

Jean-Laurent Paparin

David Dukhan

Cyril B Dousson

Houcine Rahali

Izzat Tiedje Raheem

Daniel Da Costa

Dominique Surleraux

Claire Pierra

John D Schreier

Timothy John Hartingh

Guillaume Brandt

Karine Fabienne Malagu

Peter J Machin

Francois-Rene Alexandre

Christophe Parsy

Mark Stuart Chambers

Thierry Convard

Benoît De Chassey

Paul Colin Michael Winship

Eric Meldrum

Michel Derock

Roberta Lanaro

Gilles J Gosselin

David James Witter

David L Sloman

Phieng Siliphaivanh

Michelle R Machacek

Craig R Gibeau

Michael Hale Reutershan

Timothy J Henderson

Manuel De Lera Ruiz

Frederic Leroy

Yingchun Ye

David Robert Vesey

Chunhui Huang

Ryan Quiroz

Sebastian Schneider

Rachid Rahali

Charles S Yeung

Sulagna Sanyal

Shuhei Kawamura

David Annunziato Candito

Steven Mark Silverman

Nicolas Proisy

Calum Macleod

Jamie David Knight

Christophe C Parsy

Aurélien Salanson

Jean-Francois Griffon

François-René Alexandre

Arlène Roland

Murray Wan

Jonathan M E Hughes

Patrick S Fier

Christophe Claude Parsy

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

PRMT5 inhibitors

The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.

Non-fused thiophene derivatives and their uses

The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.

Fused thiophene derivatives and their uses

Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral benzyl-amine phosphodiamide compounds

The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.

Nucleotides for the treatment of cancer

Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral phosphodiamide prodrugs of tenofovir

Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral aryl-amide phosphodiamide compounds

Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Antiviral aliphatic ester prodrugs of tenofovir

Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Antiviral prodrugs of tenofovir

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, R, R, R, Rand Z are as defined herein. 

3'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Provided herein are phosphothiophene and phosphothiazole compounds, for example, of any of Formulae I, IA, IIA, IIIA, IVA, VA, VIA, VIIA, IB, IIB, IIIB, IVB, VB, VIB and VIIB disclosed herein, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host infected with HCV.

Phosphothiophene and phosphothiazole HCV polymerase inhibitors

Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas IV, IV', I&#x2033;, II&#x2033;, or IVa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Phosphadiazine HCV polymerase inhibitors IV

Growing community of inventors

Vendemian, France

Jean-Laurent Paparin